# Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL

> **NCT07643805** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 46 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** EZH2i+GLofit-GemOx

## Key facts

- **NCT ID:** NCT07643805
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-01-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643805, "Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*